Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

GSK pounces on Human Genome with $2.6 billion bid

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/19/2012 | 10:05pm CEST

Human Genome Sciences has rejected an unsolicited bid worth around $2.6 billion from long-time partner GlaxoSmithKline, marking a new takeover battle in a drugs sector recently swept by M&A activity.

The U.S. pioneer of gene-based drug discovery, which sells a new drug for lupus with GSK, said on Thursday the offer of $13 per share, made in a letter on April 11, did not reflect the value inherent in the company.

It has hired Goldman Sachs and Credit Suisse to help explore strategic alternatives, including a possible sale. GSK has been invited to participate in that process.

The Rockville, Maryland-based firm was formed 20 years ago with the mission to isolate genes and identify their function in order to develop new drugs. Over the years it has had a rollercoaster ride as hopes for its drugs have waxed and waned.

GSK's offer represents an 81 percent premium to its closing stock price of $7.17 on Wednesday. However, that is still well below the $30 touched a year ago and investors are hoping for more, with the shares doubling to $14.20 by 1930 GMT.

Britain's biggest drugmaker said the rebuff was disappointing as its offer would give investors "immediate and certain value" superior to what Human Genome could achieve as a standalone company.

GSK chief executive Andrew Witty wrote to Human Genome boss Tom Watkins on April 11 setting out the proposal, saying he was prepared to commence a cash tender offer with no financing or due diligence condition.

Buying Human Genome would give GSK full rights to partnered drugs, which include not only Benlysta - the first new drug for lupus in half a century - but also promising experimental drugs for heart disease and diabetes.

Many drugmakers are seeking to do deals to bolster their pipelines, as older products go off patent, and GSK's readiness to buy Human Genome is a sign of confidence in the drugs that the companies have been developing together.

GSK also expects $200 million in cost synergies by 2015, with the acquisition boosting earnings from 2013.

"WHITE KNIGHT" UNLIKELY

Cowen & Co analyst Eric Schmidt said GSK was likely to seal a deal in the end.

"The 81 percent premium versus yesterday's close is a big number, and I'm sure GSK is likely to pay a little bit more to get the deal done. I think it's very likely to be sold to GSK at around $15 or so a share," Schmidt said.

"I doubt anyone else will come in. It's going to be hard for another company to pay that sort of a premium not having the inside scoop on Benlysta or on anything else these two companies are collaborating on."

Tim Anderson of Bernstein said outside interest in Human Genome's drugs was possible but any other non-GSK acquirer would only get partial control, which could deter bidders.

Barclays analysts also see no "white knight" counter-bidder on the horizon, even though the deals between GSK and Human Genome have no tricky change-of-control clauses.

GSK has long been rumoured as a potential acquirer of Human Genome, since it has been in partnership with the firm since 1993 and is already collaborating on a number of medicines.

Still, the decision to pull the trigger on a takeover attempt may surprise some investors because GSK management has tended not to buy out partners it is working with in the past.

BEYOND BENLYSTA

Analysts said GSK clearly saw value beyond Benlysta.

The two companies are also collaborating on a high-profile experimental heart drug called darapladib, which is in Phase III development, and albiglutide for diabetes, which could be filed for approval late this year or early in 2013.

Mark Clark, an analyst at Deutsche Bank, said darapladib was the biggest ticket pipeline opportunity, with up to $10 billion annual sales potential, although researchers will not know if it actually works until key trial results in 2013 or 2014.

Benlysta, which is subject to a 50:50 profit share deal between the two companies, has got off to a slow start but is still seen as having potential sales of $2.15 billion by 2016, according to consensus forecasts from Thomson Reuters Pharma. A year or so ago investors had been hoping for $3-4 billion.

Despite disappointment about Benlysta sales to date, investors are likely to be emboldened in thinking they can get a better price for their Human Genome shares by recent developments that show Big Pharma's hunger for biotech assets.

Only on Wednesday, Illumina Inc saw off a $6.8 billion bid from Roche Holding AG.

Roche, too, chose to make an unsolicited offer after Illumina shares had fallen back and Sanofi SA took the same approach in its successful acquisition of Genzyme for $20.1 billion last year.

Human Genome said it had asked for more information from GSK about progress with the experimental drugs the two companies have worked on together, including darapladib and albiglutide.

GSK, which is being advised by Lazard and Morgan Stanley, said the plan to acquire Human Genome would not affect its intention to repurchase between 1 billion and 2 billion pounds ($1.6-3.2 billion) in shares in 2012.

Shares in the British-based drugmaker rose nearly 1 percent. ($1 = 0.6238 British pounds)

(Additional reporting by Sophie Sassard, with Lewis Krauskopf and Paritosh Bansal in New York; Editing by David Cowell and Gunna Dickson)

By Ben Hirschler

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE
06/27 GLAXOSMITHKLINE : GSK starts phase III study with mepolizumab in patients with n..
06/27 GLAXOSMITHKLINE : GSK receives CHMP positive opinion for Synflorix pneumococcal ..
06/23 GLAXOSMITHKLINE PLC (ADR) (NYSE : GSK) Presents Positive Data From Phase III Shi..
06/22 GSK'S NEW CEO AIMS TO DIVEST SPORTS : sources
06/22 GLAXOSMITHKLINE : Reports Findings in DNA Research (Ruthenium Promoted On-DNA Ri..
06/22 RESEARCHERS FROM GLAXOSMITHKLINE PLC : A vaccine...
06/22 GLAXOSMITHKLINE : New Findings from GlaxoSmithKline plc in the Area of HIV/AIDS ..
06/22 GLAXOSMITHKLINE : Study Results from GlaxoSmithKline plc in the Area of Influenz..
06/22 GLAXOSMITHKLINE : reports positive results with its shingles vaccine
06/21DJGLAXOSMITHKLINE : Shingles Treatment Meets Objective in Phase III Trial
More news
Sector news : Pharmaceuticals - NEC
06/27DJMERCK AND : Says Its Network Was Hit by Global Hack
06/26DJASTRAZENECA : ADRs End Mostly Higher
06/26 VALEANT PHARMACEUTICALS INTL : Hedge fund Paulson & Co discloses 6.3 percent sta..
06/26DJHow Third Point's Nestlé Move Could Affect L'Oréal
06/23DJSAMSUNG ELECTRONICS : Makes Play for Drug Market With Version of Humira -- Updat..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
06/27 TIGENIX : This Stem Cell Pioneer Is Up 40% Since IPO With More Upside To Come
06/27 Glaxo launches late-stage study of mepolizumab in patients with nasal polyps
06/27 CAR-T Value Calculation In The Firing Line
06/25 GLAXOSMITHKLINE : 3 Reasons You Should Be Concerned
06/25 WEEK IN REVIEW : Shenzhen's BGI Plans $250 Million China IPO To Support Genomics..
Advertisement
Financials ( GBP)
Sales 2017 30 119 M
EBIT 2017 8 292 M
Net income 2017 4 381 M
Debt 2017 13 929 M
Yield 2017 4,71%
P/E ratio 2017 19,17
P/E ratio 2018 16,74
EV / Sales 2017 3,23x
EV / Sales 2018 3,11x
Capitalization 83 481 M
More Financials
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 17,9  GBP
Spread / Average Target 5,4%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Patrick J. T. Vallance Executive Director, President-R&D
Roy Malcolm Anderson Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE8.67%106 833
JOHNSON & JOHNSON18.34%367 520
NOVARTIS12.55%225 386
ROCHE HOLDING LTD.8.21%224 497
PFIZER3.97%203 487
MERCK AND COMPANY11.33%180 958
More Results